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Aims: To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough 
cancer pain (BTcP), comparing actual results from clinical practice with clinical oncologists’ prior 
perception. 
Design: Observational and descriptive study, using information collected by practising medical 
oncologists, at three moments: a) questionnaire regarding their professional judgement of the handling of 
patients with BTcP in their practice, b) cross-sectional clinical screening, to detect possible existing cases 
of BTcP in a representative sample of their patients, c) retrospective self-audit of clinical case histories of 
patients diagnosed with BTcP to find out about how it has been handled. 
Participants and study period: A random sample on a state level of 108 specialists in medical oncology. 
540 patients who suffer some type of cancer pain on the designated study date for each specialist (July-
December’16). 
Results: The global prevalence of BTcP in the study sample covered 91.3% of the patients who were 
suffering some type of cancer pain. Barely 2% of the doctors surveyed suspected figures around this 
mark. 40.9% of the cases had not been previously detected as BTcP by their doctors. Although 90% of the 
patients who had previously been diagnosed with BTcP received a specific analgesic treatment for the 
symptoms, 42% of those patients with known BTcP were not able to control their episodes of pain. 
Conclusions: Clinical inertia is a serious problem in the handling of BTcP in medical oncology services, 
where it is the subject of a significantly low level of detection and treatment, despite the contrasting 
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Episodes of breakthrough cancer pain (BTcP) are one of the painful manifestations of the cancerous 
disease. Despite its high prevalence and significant impact on the quality of life of cancer patients [1,2], it 
is an area which could be improved in terms of knowledge, identification and clinical treatment in our 
field. It involves transient exacerbations of pain which, by definition, occur in patients who are carrying 
some type of chronic pain which is stabilized and adequately controlled with conventional treatment [3-
5].  
The crisis may appear incidentally (related to a certain triggering factor, such as walking, coughing, or 
during the practice of some kind of clinical procedure) or spontaneously and unpredictably. Although the 
clinical characteristics of BTcP can vary inter- and intra-individually, they are generally episodes which 
appear rapidly and reach their peak intensity within 3 to 5 minutes, being of moderate to high intensity 
and variable duration (between 1 minute and 4 hours, with an average of 30 minutes). Its frequency, 
which typically ranges between 1 to 4 episodes a day, has a crucial impact on the psychological and 
functional deterioration of the patient and the degree of anxiety arising as a result in caregivers [6-7]. 
Its diagnosis and evaluation are not complex if specialists have a high level of suspicion of it in the 
monitoring of their cancer patients and perform a specifically oriented anamnesis towards its 
identification and perform differential diagnoses from other types of pain, using tools such as Davies’ 
algorithm [8-12]. In addition, the new fast-action opioid formulations administered by transmucosal route 
have substantially improved the scope for control [13].  
However, in our country, it is estimated that up to 77% of episodes of BTcP may not have been detected 
or treated, or they are handled inappropriately and insufficiently treated (frequently increasing the dose of 
the opioid used to control baseline pain, or adding a short-action opioid to the previous treatment, such as 
morphine, hydromorphone or oxycodone, which are inadequate for controlling this problem due to their 
slow action speed) [14]. 
As in other chronic diseases, part of this varying and inappropriate clinical practice is due to the 
recognized problem of clinical inertia (CI), which is understood as the failure during patient follow-up 
on the part of doctors to study, recommend and prescribe changes in the treatment that are necessary and 
indicated, leading to detrimental consequences to the health of their patients. CI is considered to exist in 
situations in which, due to inaction on the part of the doctors, it is not possible to meet the realistic 
therapeutic goals established in any referential framework of good practice (expert guide). In other words, 
when there is no change to the medication in order to reach the objectives proposed in the guides, without 
any adverse effect or any contraindication of the treatment required having been documented previously 
[15]. 
Although the most common cause of CI in cancer pain is not increasing the intensity of a treatment the 
patient insufficiently responds to [16], the widely acknowledged ‘therapeutic inertia’ also includes cases 
in which the treatment is not initiated or changed when indicated, despite poorly controlled pain 
symptoms. There are also cases of the use of incorrectly indicated treatment as a result of lack of evidence 
which supports its use [14]. In the particular case of BTcP, many other patients do not benefit from 
receiving appropriate treatment due to ‘diagnostic inertia’. This means that an explicit diagnosis is not 
established despite the existence of particular and characteristic clinical signs of the process. 
This current study attempts to estimate the frequency of CI in the habitual handling of BTcP among 
medical oncology specialists in our country. It also aims to encourage doctors to raise their own 
awareness and pay attention to this matter, comparing their initial perception on the scope of BTcP among 
their patients (prevalence and impact), with the actual situation verified through the result of a collective 
experience (voluntary and confidential) of systemic identification of possible cases of undetected and 
under-treated BTcP in their consultations.  
The study also allows for examination of the variables associated with CI (professional experience, age 
and clinical profile of the patients, prior incidents in the administration of opiates, familiarity with the 
available vade mecum and the alternative administration routes, degree of prior training with analgesia, 
knowledge of the BTcP guidelines, attendance at conferences or scientific meetings on this matter, etc.). 
All this can offer plenty to reflect on when addressing possible ways of improving the situation.  
 
 





Material and Technique: 
An epidemiological study is carried out on the prevalence of BTcP and the quality of clinical attention 
offered in oncology consultations in Spain. This is done under the hypothesis that CI exists in dealing 
with this problem. In other words, there is a certain degree of under-diagnosis and inappropriate 
treatment. The aim is to establish the real extent of the problem and compare its actual scope with the 
initial perception of the oncologists themselves.  
Study design: An observational and descriptive study is performed, using information collected by a 
large group of medical oncologists, at three consecutive times: 
• Firstly, each specialist conducted an exploratory professional questionnaire about their preliminary 
impression of the prevalence, handling and clinical results obtained in patients who suffered from 
BTcP in their consultations. In addition, they gave details of their own degree of knowledge and 
monitoring in their routine work with regard to the clinical practice standards proposed in a widely 
distributed recent expert guide on BTcP [14] in our field.  
• Secondly, after completing the previous questionnaire, the doctors took part in a descriptive cross-
sectional study to perform a clinical screening of BTcP among the patients with any type of cancer 
pain habitually seen in their consultations. After verifying the eligibility criteria, the Davies 
diagnostic algorithm [10] was systematically applied to the patients. During this same consultation, 
descriptive clinical information was collected in each case of an identified BTcP. 
• Finally, in the third instance, through a retrospective chart-review study, the information on the 
recruited patients was completed regarding the detection prior to the study of the cases of BTcP 
confirmed in the screening and their prior clinical handling. This task required each doctor to review 
their medical case histories, in the form of a voluntary and confidential self-audit of their clinical 
practice.  
Before its launch, the project went through the compulsory evaluation and authorization by a Research 
Ethics Committee (in this case the Comité Autonómico de Ética da Investigación de Galicia. Consellería 
de Sanidade.  Xunta de Galicia (The Autonomous Research Ethics Committee of the Health Service of 
Galicia)). 
Participating doctors and patients:  
132 medical oncologists were invited to participate, selected randomly from a register of 1,200 
specialists, which is the property of the research sponsor. This study population represented more than 
90% of the complete target group of the specialty, according to prior census not available [17]. The 
sample was stratified by autonomous communities to ensure a wide geographical distribution of doctors 
and patients representing the whole of the Spanish health service. Although all of them voluntarily 
accepted to take part in the study. By the end of it, a total of 108 specialists had completed all of the tasks 
that made up the study. In the case of the 24 who did not complete all the information, the majority [19] 
cited their unforeseen absence from consultation on the dates of the study, or their inability to collaborate 
due to heavy workload (5 cases). 
The cases which were eligible for the BTcP screening were all patients who, prior to the start of the study, 
had been treated by the participating doctors as carriers of some type of cancer pain symptoms (regardless 
of the type, degree of activity and possible treatment received). Patients who had participated in a clinical 
trial related to their pain or cancer symptoms in the last year were excluded. To avoid bias in the selection 
of specific cases, oncologists were told to perform the selective screening of possible BTcP on the first 
five eligible patients who were attended to during a routine clinical working day, randomly pre-scheduled 
with each doctor. Each researcher therefore provided an identical quota of cases [5] to the total study 
sample, which brought together complete and valid information on 540 patients.  This sample size 
ensured a maximum error in the central estimate of the study (percentage of patients, previously identified 
or not as carriers of BTcP) of 4.2%, for a confidence level of 95%, even in the most unfavourable result 
circumstances of a binomial distribution (p=q=0.5). 
Study variables:  
The variables for the professional were: basic demographic and professional information of the 
participating oncologists; professional opinion on the prevalence of BTcP in their consultations and on 
the possibility and consequences of their being unknown or inappropriately treated cases of BTcP among 





their patients; routine clinical habits regarding BTcP (self-declared degree of monitoring on the main 
recommendations of a recent expert consensus on this matter) [14]. 
The patient variables were:  
• Information collected through a patient interview: basic demographic data, result of the 
screening after applying Davies’ algorithm (presence/absence of BTcP) and characteristics of the 
episodes (intensity, duration, frequency, time of evolution and impact on the patient's daily life).  
• Information collected from their clinical case history: complementary clinical and 
epidemiological information of interest regarding the patients, prior identification or not of the 
cases of BTcP by the doctor, recommended treatment prior to the study (if there was any) and 
therapeutic results obtained.  
Instrumentation:  
The researchers used two tools to collect the information needed for the study: 
• The doctor survey was self-administered through an anonymous electronic questionnaire, accessible 
from a specific website. The date for completing this survey was pre-arranged and signalled the start 
of the field work for each specialist.   
• The field work (the prospective systematic screening of possible cases of BTcP) was made on a data 
collection logbook (DCL) in paper format which each doctor used during clinical interviews with 
their eligible patients according to protocol. After finalizing the recruitment of their patients, the 
doctors completed the information remaining in the DCLs regarding the patients with BTcP with the 
data collected from reviewing the case histories. All this data was transferred to the project website 
by completing a specific questionnaire for each patient. 
Time period and plan of study: 
The field work was completed by all specialists within eight calendar weeks, between July and December 
2016. Each researcher was assigned a random date to start the process described. This was a convenient 
and viable moment in line with their appointment schedule when it was possible for them to complete the 
personal questionnaire. The first available day of normal clinical practice (after doing the personal 
questionnaire) was selected as the day of screening (BTcP day). On this day, it was foreseeable that the 
specialists would attend to and recruit the expected quota of patients who they were monitoring as a result 
of a cancer process which would include pain symptoms. If, during the specified date, it was not possible 
to fill the quota of cases due to the lack of eligible patients, the consecutive recruitment was extended for 
the next few days as necessary. 
All the information for the study was collected solely by the oncologists which they transferred 
themselves, anonymously and after safely identifying themselves on the project website. The data was 
introduced in a single electronic database on a state level. Neither the researchers nor the analysts could 
identify the particular patients or specialists during its use. This was required to avoid any intentional bias 
in the information collected by the specialists about their clinical habits and routine treatment. 
Statistical analysis:  
The version 13.0 of the integrated SPSS-W package was used to do the description of the qualitative 
variables (through calculation of the relative frequency distribution (%) and appropriate graphical 
representations) and quantitative (through central tendency, dispersion and measures of position). The 
central estimates of prevalence which were the subject of study (prevalence of BTcP, under-diagnosis and 
under-treatment) were accompanied by their corresponding confidence interval at 95%.  
Results: 
1. Professional and social welfare profile of the oncologists surveyed. 
The sample of 108 oncologists, aged between 29 and 68 (average 38.4) was made up mainly of females 
(66.6%; 72). Their professional experience ranged between 1 and 37 years practice (average 9.5 years). 
Most of the doctors (95.4%; 103) worked in public health services, although others (10.2%; 11) also 
practised, either additionally or exclusively, in the private sector. The larger share of participants (59.3%; 





64) recruited their patients in an outpatient setting, followed by hospital outpatient care (26.8%; 29), 
hospitalization (12%; 13) and others (3.7%; 4).  
The care load (patients seen to by the oncologist per day) and the frequency of care for patients with 
BTcP (cases per week), estimated by those surveyed is summarized in table 1. 
 
Table 1. Care load and frequency of care for cases of BTcP; information offered by the 
oncologists.IC95% 
Care load Average Medium INF SUP P25 P75 
Patients / day 18.5 18 15 20 15 20 
Cases of BTcP / week 14.8 10 1 80 5 20 
INF SP 
 
54.6% (59) of the oncologists surveyed stated that they had read the guidelines Diagnosis and treatment 
of breakthrough cancer pain: consensus recommendations [14]. In addition, 60% (65) had recently 
participated in some type of clinical session at their hospital/clinic on the subject of BTcP. 49% (53) had 
attended a conference or meeting specifically on BTcP and 41% (44) had recently completed some type 
of training course on BTcP. 
 
2. Prior impression (opinions) of the oncologists on the prevalence of BTcP in their consultations 
and the adequacy of its detection and treatment. 
The subjective impression on the prevalence of episodes of BTcP among their patients was variable, as 
shown in figure 1. No significant differences were seen in the perception regarding their normal 
healthcare environment (consultations, outpatient hospital and inpatients), except for the 2 specialists who 
stated that they deal with a very high prevalence (>75% of their patients), who worked in outpatient 
oncology consultations. 
 
Figure 1. Distribution of those surveyed (n=108) according to their perception of the prevalence of BTcP 
























Regarding their habitual methods for actively exploring possible episodes of BTcP among their patients, 
34.3% (37) of the specialists stated that they systematically ask their patients about it. Another 46.3% (50) 
only did it if the patient was undergoing analgesic treatment for cancer pain. 11.1% (12) said they 
considered the possibility if ‘they had the time’, and a final 8% (9) only dealt with it if the patient 
spontaneously referred to symptoms which suggested BTcP. 
The perception of the specialists on the possibility that cases of BTcP go unnoticed and can remain 
undetected in their consultations varies significantly, as shown in table 2. Among the causes attributed to 
the patient which could lead to such a situation, the doctors suggested patients hiding the symptoms due 
to fear of receiving more opiate treatment (43%); the lack of consultation by the patient as a result of 
being unaware of BTcP and the possibility of receiving effective treatment (41%); and cases of patients 
omitting the matter in consultations as they were able to tolerate the short duration of the episodes (40%). 
In addition, the specialists identified other possible causes which were their own responsibility. These 
included forgetting to specifically ask about the possibility of BTcP (31%) and the diagnostic doubts 
about whether the patient’s symptoms corresponded to a BTcP (20%). None of those surveyed doubted 
the current diagnostic criteria for BTcP. 
Table 2 also contains the variable perception of the specialists on the possibility that some of their 
patients with BTcP do not receive a specific analgesic treatment (fast-acting opiates) in addition to their 
baseline treatment. Although 47% of those surveyed attributed this to the patients and/or family members, 
who may prefer not to treat these episodes with more opioids, there are also other factors which are 
strictly down to the specialists. These include attempts to mitigate the BTcP adjusting the baseline 
analgesic guidelines (18%); doubts on which is the best treatment option for certain patients (11%); being 
unsure about choice as a result of excessive analgesic formulations for BTcP (6%); fear of side effects 
deriving from indicating free use of fast-acting opiates (5%); and lack of personal up-to-date scientific 
knowledge on the therapeutic handling of BTcP (1%). 
 
 
Table 2. Subjective impression of the specialists (n=108) on the possibility that patients with BTcP go 










Possibility of under-detection in cases of 
BTcP in their consultation 
11.1% 62% 25% 1.9% 
Possibility of inappropriate treatment in cases 
of BTcP 
15.7% 67.6% 15.7% 0.9% 
 
 
3. Description by the oncologists (self-declaration) of their routine clinical practice in the 
management of breakthrough cancer pain. 
The Davies algorithm has a wide dissemination and acceptance among experts as a clinical tool for 
detecting possible episodes of BTcP: 78% of oncologists stated they used it ‘almost always’ or 
‘frequently’, opposed to the rest who claimed they did not use it more than ‘occasionally’ or ‘hardly 
ever’. 
Table 3 offers the description that the specialists surveyed made on their habitual clinical practice before 
a suspected case of BTcP. Table 4 shows the stated therapeutic procedures after detecting cases of BTcP. 
In both cases, the specialist declares the degree of monitoring (according to their personal impression) of 
the good practice recommendations laid out in the clinical guide on BTcP which was used as a reference 
for this study [14].  






Table 3. Declaration of the specialists (n=108) on their routine diagnostic habits before a suspected case 
of BTcP.  
 







• Asking about the number of episodes  79.4% 27.8% 0.9% 0.9% 
• Asking about the physiopathology 
characteristics  
46.3% 42.6% 10.2% 0.9% 
• Asking about the characteristics of 
the pain  
62% 33.3% 3.7%  0.9% 
• Asking about triggers 57.4% 31.5% 10.2% 0.9% 
• Asking about relieving factors 42.6% 38.9% 18.5% - 
• Asking about the medication used up 
to that time  
81.5% 18.5% - - 
 





Table 4. Declaration of the specialists (n=108) on their routine therapeutic habits after diagnosing a 
BTcP.   
 






If the patient has no baseline treatment with 
opioids, I schedule this treatment to try to 
control the symptoms. 
59.3% 28.7% 9.3% 2.8% 
If the patient already has an effective 
baseline treatment schedule with opioids, I 
increase that treatment to also try to control 
the BTcP. 
17.7% 25% 25.9% 32.4% 
If the patient already has an effective 
baseline treatment with opioids, I 
immediately prescribe a specific treatment 
(fast-acting opioids), as a complement to the 
baseline treatment. 
66.7% 28.7% 4.6% - 
I prescribe co-analgesic therapeutic 
measures (anti-seizure drugs and/or 
antidepressants) to help control the pain and 
reduce the dose of opioids. 
16.7% 43.5% 36.1% 6.7% 
From the start of the specific treatment, I add 
treatment to prevent or minimize the side 
effects (nausea, vomiting, constipation). 
47.2% 40.7% 10.2% 1.9% 
For the specific control of the episodes of 
BTcP, I choose a form of fentanyl, 
independent to the baseline analgesia. 
53.7% 40.7% 4.6% 0.9% 
Depending on the clinical situation and my 
patients’ wishes, I usually use the following 






• Oral 13% 21.3% 35.2% 30.6% 
• Sublingual 43.5% 48.1% 6.5% 1.9% 
• Intranasal 7.4% 20.4% 38% 34.3% 







• I advise to start with the lowest 
available dose and increase the dose 
at time intervals, until the minimum 
effective dose is found. 
51.9% 41.7% 5.6% 0.9% 
• I recommend recording the dose, 
interval and maximum number of 
daily doses of the drug administered. 
61.1% 26.9% 7.4% 4.6% 
• I recommend a follow-up 
appointment for the patient within 
the first 72 hours, to evaluate the 
effectiveness and tolerability, to then 
adjust the dose. 
12% 30.6% 34.3% 23.1% 
• I explain to the patient and/or their 
family the importance of 
administering the treatment early 
during each episode. 
70.4% 26.9% 2.8% - 
 
 





4. Demographic and clinical profile of the patients in the study (n=540) 
It involves 540 cancer patients who had been previously identified as suffering from some sort of cancer 
pain being monitored by clinical oncologists. The sample had a wide range of ages (5 to 88) with the 
average age of 61.7 (CI95% = 60.7-62.7) and median of 63. 40% (214) were female. The ages of the males 
were significantly greater than those of the females, with an average of 63.2 compared with 59.6 (t 
Student= 3.263 p<0.001). 
The location of the primary tumours, headed by the lung, is shown in figure 2. The patients presented a 
wide variety of evolutionary stages. In this regard, it is worth highlighting a greater number of cases with 
primary involvement T3-T4 (72.4%) and of cases N1-N2 (87.8%) in terms of lymph node involvement. 
80% of cases studied were at a metastatic stage of the illness at the time of the study.  
Although all the patients recruited (n=540) were previously identified by their doctors as carriers of some 
type of pain associated to their cancer, only 428 patients (79.3%) referred to having these pain symptoms 
on the day of the consultation. Among the latter, the origin of the pain was of the somatic type (38%), 
neuropathic (24.9%), visceral (24.2%), incidental (6.7%) or undefined (6.2%). Its intensity varied 
between mild (5.1%), moderate (49.9%) and severe (45%). The baseline analgesic treatment prescribed to 
the 540 subjects of the global sample (categories were non-exclusive) prior to the study were: non-opioid 
analgesics (37.6%), ‘weak’ opioids (12.6%) or strong opioids (79.7%). In addition, 42% of the patients 
were taking some type of co-adjuvant drugs.  
































































5. Prevalence of BTcP and low detection of cases among the patients participating in the study. 
The results of the 540 patients recruited being submitted to the screening for BTcP using the Davies 
algorithm are summarized in figure 3. 
Fig. 3. Overall outcome of the screening process for BTcP by applying the Davies algorithm to the 540 
patients involved in the study. 
 
Of the 540 cancer patients evaluated in this study using the Davies algorithm, 493 of them were 
diagnosed as carriers of BTcP, either previously detected (291), or detected in the prospective screening 
process made for this study (202).  
Regarding the proportion of patients who had been identified by their doctors as carriers of BTcP before 
the study, the prevalence of the problem detected was 53.9% (291/540; CI95% = [51.9-55.9]). Adding 
this figure to the hidden cases detected during the screening, the true prevalence of BTcP among patients 
who are carriers of some previous cancer pain is increased to 91.3% (493/540; CI95% = [88.9-93.7]). 
Among the total number of patients who are carriers of BTcP episodes in our study, the 202 subjects who 
were previously not identified by their doctors as such, represent a low diagnosis of 40.9% of the existing 
cases (202/493; CI95% = [36.6-45.2]). It is therefore clear that from the total number of patients being 
clinically monitored for some type of cancer pain which had previously been established, 37.4% 
(202/540; CI95% = [33.3-41.5]) suffer episodes of BTcP which are unknown (and not treated) by their 
doctors.   
6. Clinical profile of the cases of BTcP (n=493). 
The most common aetiology of the BTcP is tumoural (91.2%) as opposed to non-tumour cases. 45.5% of 
the time, the pain was of a mixed physio-pathological type, while in 36.6% of cases, it was of nociceptive 
type and 17.9% neuropathic.  60% of the patients referred to the presence of an incidental type trigger, 
while 37% an idiopathic type. The remaining 3% of the cases were interpreted as an ‘end-of-dose’ 
phenomenon. The intensity of the pain of these episodes was very variable, between unbearable (13.4%), 
high (56.6%), moderate (28.4%) or low (1.5%). The patients referred to between 1 and 15 episodes of 
BTcP a day, with an average of 3.6 episodes (CI95% 3.5-3.8) and median of 3 episodes. 
540 cancer patients 
evaluated (100%) 
428 patients referred to 
suffering pain symptoms on 
the day of the study (79.3%) 
112 patients did not refer to 
suffering pain symptoms on 
the day of the study (20.7%) 
291 cases of BTcP 
had previously been 
detected (53.9%) 
27 patients were 
free from BTcP 
(5%) 
92 cases of BTcP 
not previously detected 
(17%) 
20 patients were 
free from BTcP 
(3.7%) 
 
110 cases of BTcP had 
not been previously 
detected (20.4%) 





7. Therapeutic approach and results obtained in the patients with BTcP (n=493), in accordance 
with the information obtained from the audit of their clinical case history. 
68% (340/493; CI95% = [63.9-72.1]) of the patients with BTcP were receiving fast-acting opioid 
treatment on the day of the study. As only 291 of the patients with BTcP had been previously diagnosed 
by their doctors, a certain number of undetected cases of BTcP were also receiving treatment with drugs 
which were adequate (fast-acting opioids) for the disorder. Analysing this in more detail, it can be seen 
that 264 of the 291 patients (90.7%; CI95% = [87.4-94.0]) diagnosed prior to the study as carriers of 
BTcP and 76 of the 202 patients (37.6%; CI95% = [30.9-44.3]) not specifically detected as carriers of 
BTcP prior to the study were being treated with fast-acting opioids at the time they were evaluated. Of all 
these treatments, the most common administration route prescribed was sublingual, in 61% of cases. This 
was followed by the oral route in 22.6% of cases. According to the clinical judgement of the oncologists 
themselves, 41.6% (121/291; CI95% = [35.9-47.3]) of the patients identified as carriers of BTcP prior to 
the study were not able to suitably control their pain episodes.  
With regard to the tolerability of the treatment with opioids specifically for the BTcP, 68% of the patients 
treated with these drugs (231/340; CI95% = [63.1-72.9]) had been prescribed some type of preventative 
drug for the foreseeable side effects at the start of treatment for BTcP. Despite this, on the whole, 17.9% 
of the patients who were administered fast-acting opioids (61/340) presented undesirable effects. Most 
notably, in decreasing order, constipation (57%), nausea or vomiting (25%) and sedation (18%).  
With regard to any deviation from the quality criteria recommended by the guide for monitoring patients 
with a specific treatment for BTcP, the oncologists detected in their own clinical case histories that 14.1% 
(41/291) of the patients had not been advised titration dose up to the minimum effective at the time of 
prescribing the treatment with fast-acting opioids. In 12.7% of the cases (37/291), it had not been 
considered worthwhile to make adjustments to the dose in previous consultations despite the persistence 
of episodes of BTcP. Also, in 8.3% (24/291) of the cases, before considering changes, the compliance of 
the patient was not previously verified, or whether they were applying it as an early treatment as soon as 




This current study presents data showing a prevalence of BTcP in a broad group of patients (n=540) who 
are prior carriers of some type of cancer pain and analyses the clinical results obtained in their treatment. 
This was carried out via a self-audit conducted by the doctors (108 specialists in medical oncology on a 
state level, of varied profile, with a significant level of attention and clinical practice, generally in the 
outpatient setting).  
 
Several precautions were taken to increase the accuracy and confidence level of the estimates made based 
on the findings of the study. The size and wide geographical dispersion of the sample of participating 
physicians and patients, stratified by autonomous communities, incorporates any possible professional 
and clinical or epidemiological variations between the different participating health services. The random 
assignment of a recruitment day for each doctor and the systematic recruitment of patients as of that date, 
increases the external validity of the findings of the prevalence of BTcP with regard to the state-level 
target group of cancer patients who are carriers of some type of cancer pain symptoms. Moreover, the 
voluntary nature and anonymous character of the information referred by specialists and patients 
minimize the risk of intentional bias when providing the information. This could have been motivated by 
the desire to project a favourable professional image, leading to falsification of the results provided.  
 
The study confirms, as was raised in the starting hypothesis, that there is a significant prevalence of BTcP 
and a notable diagnostic inertia (low detection of clinically manifested cases) and therapeutic inertia (not 
starting treatment in patients who have been diagnosed, or not modifying unsuitable or ineffective 
treatment regimes) in its handling in the oncology health services. These deficits do not appear to depend, 
essentially, on the bias of the selection of the group of participating specialists or patients, who were 
chosen as an attempt to be representative of both groups.  
 
BTcP does not seem to be a topic of much interest among the physicians who were surveyed: almost half 
of them declared that they had not recently received any type of specific training on BTcP (via sessions, 
conferences or specific programmes) and had not read the guide of consensus recommendations for the 
diagnosis and treatment of BTcP, which has been widely distributed and is accessible to all. This material 





has been used as a reference for good practice in this study. This data can determine the deviation of the 
personal impressions of the doctors regarding the current situation of BTcP in Spain.  
 
In this sense, the perception and opinion of the oncologists, which were offered prior to the self-audit on 
their clinical practice, were generally optimistic in the face of the real situation, both on the prevalence of 
BTcP among cancer patients and the professional habits in the active search for cases of BTcP in their 
consultations and the suitability and results of the treatment of identified cases.  
 
The figure of prevalence of BTcP obtained after the screening of patients in consultation (91%) was much 
higher than what the oncologists predicted beforehand (their opinions) and the evidence in the audit of the 
clinical records prior to the study (54%). The prevalence of BTcP among patients being monitored in 
oncology services exceeds the figures of previous studies in the same field. It actually comes close to the 
number of patients attended to in palliative care units or pain units [18-21].  In the light of this data, the 
patients with some type of previous cancer pain symptoms should be considered as a population at a very 
high risk of presenting episodes of BTcP. However, this does not seem to be the general opinion a priori 
among oncologists, the majority of whom underestimated this factor among their patients. Less than 2% 
of specialists had a previous realistic perception of the situation and considered that the frequency of the 
problem could be ‘greater than 75% of their patients’, getting closer to the actual figures gleaned from the 
study sample.  
These opinions are logically compatible with a notable under-detection of BTcP by oncologists, verified 
after performing a systematic screening of potential cases. Although the noticed prevalence (cases known 
about by the specialists prior to the study) represented slightly more than half of the cancer patients 
evaluated, a striking additional hidden prevalence was detected (cases unknown to the doctors which 
surfaced during the screening), which reached up to more than another third (37.4%) of the patients being 
monitored for some type of cancer pain.  On the whole, the under-diagnosis of BTcP exceeds 40% in all 
cases of actual BTcP present in the study sample. From this data, the potential consequences on the 
deterioration in the quality of life of these patients who were undetected and did not receive appropriate 
treatment for their episodes of BTcP can be inferred. 
Although the majority of oncologists (>80%) refer to questioning their patients about the possibility of 
BTcP, only 34% of them do it systematically on all the cancer patients they treat, whether they are 
carriers or not of some type of pain symptoms associated to cancer. The poor diagnostic results obtained 
from the study are also in contrast to the prior general perception of the majority of the specialists (almost 
three-quarters of the doctors surveyed) that it is ‘unlikely’ that patients with BTcP go unnoticed in their 
consultations. The specialists should reflect on the apparent disparity between their perceptions and their 
actual clinical practice, and on the chance to actually include in their anamnesis some type of clinical tool 
of proven performance, such as Davies’ algorithm.  
Regarding the treatments offered and the therapeutic results obtained in patients with BTcP, the study 
also identifies significant room for improvement. Most of the cases of BTcP unknown to specialists 
(hidden prevalence) logically did not receive a specific treatment for controlling their symptoms 
(although a third of them were being treated with fast-acting opioids at the time they were evaluated, 
without expressly being diagnosed with BTcP). Almost 10% of the patients who had already been 
diagnosed with BTcP before the study were not receiving any appropriate drugs for treating their 
breakthrough episodes despite them being indicated. In addition to this therapeutic inertia, the most 
characteristic factor of therapeutic inertia could be seen in slightly less than 13% of clinical case histories 
evaluated. This refers to inaction on the part of the doctor (not adjusting the dose) despite awareness of 
the ineffectiveness or partial effectiveness in controlling the episodes. What is more, when this treatment 
with fast-acting opioids was prescribed, a large share of the patients who received them (41.6%) were still 
not able to adequately control their pain episodes, according to the oncologists themselves.  
On a positive note, in general, it is worth highlighting that the use of specific opioid treatment for BTcP 
seems to be safe and convenient, as it usually comes with recommended treatment for the prevention of 
possible side effects and it has a low incidence of undesirable effects. Similarly, there is a general 
alignment between the high rates of acceptance and theoretical interest in the recommendations of the 
guidelines for monitoring patients with specific opioid treatment for BTcP and the good practices 
identified in the audit of most of the clinical case histories. These refer to the dose titration up to 
achieving the minimum effective dose, the necessary adjustments to dose in cases of crises which are not 
effectively controlled, and checking in consultations on the compliance and early use of fast-acting 
opioids by the patient, before considering modifying the schedule.  





The possible reasons behind this approach to improving cancer pain and the apparent neglect by 
oncologists of the problem compared to other clinical priorities are varied and of different responsibility. 
On the part of the specialists themselves, without a doubt, they as a group should ensure that they are 
sufficiently updated on BTcP and the current recommendations for identifying and handling it, to reduce 
diagnostic and therapeutic uncertainty related to the unfamiliarity in handling this problem.  
However, other circumstances appear in the care context and related to the patients themselves, which are 
also barriers to early detection of BTcP and can lead to the therapeutic inertia referred to above. Medical 
oncology as a specialty is subject to in-depth review of its boundaries (immunology, genetics, and so 
forth), in the search for specially tailored high-precision treatments. All this requires a determined effort 
by the specialists to update their professional know-how in the new paradigm of health care, which offers 
both benefits and risks. The complexity and hyper-technification of oncology today can occupy the 
attention and interest of many oncologists and specialists, drawing their focus away from the 
comprehensive understanding of the effects of the illness on the patient and quality of life. It threatens to 
perpetuate the current unsatisfactory situation, in which cancer pain remains damaging and poorly dealt 
with.  
Organizational aspects of the health care system also have an impact, such as high pressure on 
consultations, little time available to dedicate to each patient, and the lack of cooperation among 
interdisciplinary healthcare teams. These all make it difficult to devote sufficient time and effort to 
controlling pain as an objective in consultations for improving the quality of life of patients (along with 
the indisputable objectives of controlling the illness or monitoring the treatment to increase the survival of 
the patient).  
Other factors can depend on the cancer patients themselves: lack of information about the existence of 
BTcP and the treatment available may lead to them neglecting to mention this matter in their 
appointments with the specialist. On other occasions, the patients or their families are opposed to or 
reluctant to treatment with opioids in addition to the baseline analgesic treatment, or they cannot 
guarantee reliable cooperation in assuming autonomy in the titration, adequate use of the drugs in the 
crises, and evaluation of possible side effects. All of these present additional barriers, external to the 
specialist, for early identification and achieving control of episodes of BTcP in patients.  
 
Action to improve this situation can be geared in several ways:  promote efficient continuous medical 
education programmes, use reminders for the diagnosis and control in electronic medical records, develop 
simple protocols which include recommendations specifically aimed at overcoming clinical inertia, 
involve nursing staff and the patients themselves, who need to be suitably informed, in the detection of 
new cases and in the request for medical aid in its control. These are some of the measures which may 
help achieve the desired results [16]. However, there is no doubt that an urgent reflection on the part of 
the medical practitioners is required to address the situation detected in the present study and to raise 
personal awareness, beyond what are personal beliefs and opinions on the problem, as there is extensive 
room for improvement in current oncology practice in dealing with episodes of BTcP. Only in this way 
can each oncologist be involved in rectifying the part of responsibility which corresponds to them in the 
serious problem of under-detection and under-treatment of BTcP in oncology services.  
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